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ABSTRACT
Background. The sodium–glucose co-transporter 2 inhibitor
dapagliﬂozin decreases haemoglobin A1c (HbA1c), body weight,
blood pressure (BP) and urinary albumin:creatinine ratio
(UACR) in patients with type 2 diabetes. The efﬁcacy and safety
of this drug have not been properly deﬁned in patients with type
2 diabetes and Stages 3b–4 chronic kidney disease (CKD).
Methods. In a pooled analysis of 11 phase 3 randomized con-
trolled clinical trials, we determined least square mean changes
in HbA1c, body weight, BP, estimated glomerular ﬁltration rate
(eGFR) and UACR over 102weeks in patients with type 2 dia-
betes and an eGFR between 12 to less than 45mL/min/1.73 m2
receiving placebo (n¼ 69) or dapagliﬂozin 5 or 10mg
(n¼ 151). Effects on UACR were determined in a subgroup of
patients with baseline UACR30mg/g (n¼ 136).
Results. Placebo-corrected changes in HbA1c with dapagliﬂo-
zin 5 and 10mg were 0.03% [95% conﬁdence interval (CI)
0.3–0.3] and 0.03% (95% CI0.2–0.3) during the overall 102-
week period. Dapagliﬂozin 5 and 10mg compared with placebo
reduced UACR by 47.1% (95% CI 64.8 to 20.6) and
38.4% (95% CI 57.6 to 10.3), respectively. Additionally,
dapagliﬂozin 5 and 10mg compared with placebo reduced BP
and body weight. eGFR increased with placebo during the ﬁrst
4weeks but did not change with dapagliﬂozin. There were no
between-group differences in eGFR at the end of follow-up.
Adverse events associated with renal function occurred more
frequently in the dapagliﬂozin 10-mg group. These events were
mainly asymptomatic increases in serum creatinine.
Conclusions. Dapagliﬂozin did not decrease HbA1c in patients
with type 2 diabetes and Stages 3b–4 CKD, but decreased UACR,
BP and body weight to a clinically meaningful extent. These results
support a large outcome trial in this population to conﬁrm long-
term safety and efﬁcacy in reducing adverse clinical endpoints.
Keywords: dapagliﬂozin, diabetic nephropathy, kidney,
SGLT2 inhibitor, type 2 diabetes
INTRODUCTION
Approximately 30–40% of all patients with diabetes also have
chronic kidney disease (CKD) [1]. Both diabetes and CKD ac-
count for an increased risk of premature mortality, cardiovascu-
lar morbidity and end-stage kidney failure [2]. Few effective
therapies are available for such patients and novel therapeutic
options aimed at improving clinical outcomes in this high-risk
population are therefore highly desirable.
Sodium–glucose co-transporter 2 (SGLT2) inhibitors are anti-
diabetes drugs that block the reabsorption of glucose and sodium
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.
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in the S1 segment of the proximal tubule, thereby augmenting
urinary glucose and sodium excretion [3]. Inhibition of urinary
glucose reabsorption results in a reduction in plasma glucose and
haemoglobin A1c (HbA1c). Inhibition of sodium reabsorption,
on the other hand, leads to increased delivery of sodium to the
macula densa, which stimulates tubuloglomerular feedback and
afferent arterial vasoconstriction and reduces glomerular hyper-
filtration. This is clinically manifested as an acute reduction in
glomerular filtration rate (GFR) and albuminuria. The GFR de-
cline is completely reversible after drug discontinuation [4, 5].
Only a few clinical studies have explored the efficacy and
safety of SGLT2 inhibitors in patients with impaired kidney
function [6–8]. These studies have predominantly included
patients with Stage 3 CKD [estimated GFR (eGFR) 30–60mL/
min/1.73 m2], and have demonstrated that the glucose-lowering
efficacy of SGLT2 inhibitors in these patients is diminished com-
pared with patients with preserved kidney function [6, 8]. This
attenuated hypoglycemic action is most likely a result of reduced
glucose filtration. Whether SGLT2 inhibitors are effective and
safe in patients with more severely impaired kidney function (i.e.
Stages 3b and 4 CKD, characterized by an eGFR of 15–45mL/
min/1.73m2) is not fully known. We therefore performed a
pooled analysis of multiple phase 3 clinical trials to characterize
the efficacy and safety of the SGLT2 inhibitor dapagliflozin in
patients with type 2 diabetes with Stages 3b and 4 CKD.
MATERIALS AND METHODS
Study designs and patient populations
Eleven phase 3, randomized placebo-controlled clinical trials
in patients with type 2 diabetes receiving dapagliflozin were in-
cluded in this pooled analysis. Supplementary data, Table S1
shows the characteristics of the study populations included in
this analysis. The study designs, populations and primary results
of all these studies have been previously reported [7, 9–18].
In short, all studies had a core study period of 24weeks and
the majority had an extension period of up to 102 or 104weeks
(Supplementary data, Figure S1).
The effects of dapagliflozin 5 and 10mg as monotherapy or
in combination with metformin, sulfonylurea derivatives, thia-
zolidinediones, dipeptidyl peptidase 4 inhibitors or insulin ver-
sus placebo were examined. The studies characterized the
effects of dapagliflozin treatment in patients with a range of
eGFR levels whose diabetes was inadequately controlled with
diet and exercise alone or with the above-mentioned glucose-
lowering therapies. Each study protocol was approved by inde-
pendent local/central ethics committees and informed consent
was obtained from all patients.
Measurements and outcomes
Patients with diabetes and an eGFR between 12 to less than
45mL/min/1.73 m2 were included in this pooled analysis. We
characterized the effects of dapagliflozin 5mg/day or dapagliflozin
10mg/day versus placebo on HbA1c, markers of kidney function
[eGFR, urinary albumin:creatinine ratio (UACR), potassium and
phosphate] and other cardiovascular parameters [hematocrit,
blood pressure (BP), body weight and uric acid] by assessing the
changes from baseline to 4weeks and/or to 102weeks follow-up.
Additionally, the overall least square means were calculated. Spot
urine samples were used to measure UACR.
Statistical analyses
Descriptive statistics were used for presenting baseline char-
acteristics and safety data. The mean change from baseline
value and 95% confidence interval (CI) were derived using a
longitudinal repeated measures mixed model with fixed terms
for treatment, study week and study week-by-treatment interac-
tion as well as the fixed covariates of baseline, baseline-by-study
and baseline-by-week interactions. UACR values were log-
transformed (using the natural log) and then exponentiated
back to the original scale. The Kenward–Roger method was
used. If the model did not converge, the Satterthwaite approxi-
mation was used. If this model did not converge, the Kenward–
Roger method was used, first with the baseline-by-study and
then baseline-by-week terms removed. Finally, if this model still
did not converge, analysis of covariance (ANCOVA) was done
for each week separately.
Subgroup analyses were performed to assess if the effects of
dapagliflozin on UACR at week 24 were consistent across
subgroups. The population was stratified by median baseline
UACR levels and by micro- and macroalbuminuria stages.
An ANCOVA model was used with albuminuria subgroup
added as a factor and treatment albuminuria subgroup as in-
teraction term. The week 24 data were chosen since this was the
time point used for the primary analysis in the included studies,
and data form a large number of patients were available for
meaningful analysis.
The influence of other covariates on the effects of dapagliflo-
zin on UACR was also explored. Continuous fixed covariates of
change from baseline toWeek 24 in HbA1c, systolic BP or body
weight were added to an ANCOVA model that included treat-
ment as a fixed factor. All analyses for both safety and efficacy
variables also included data from patients who had received gly-
caemic rescue therapy. Patients received open-label rescue ther-
apy with an antihyperglycemic agent if predefined rescue
criteria were exceeded. Changes in antihypertensive medica-
tions were not controlled for in this study. The statistical analy-
ses were performed with SAS versions 9.2 and 9.4 (SAS
Institute, Cary, NC, USA).
RESULTS
Baseline characteristics
A total of 220 diabetic patients with an eGFR between 12
and<45mL/min/1.73 m2 at baseline were included in this post
hoc analysis. The baseline characteristics of this population are
reported in Table 1. The mean baseline eGFR with placebo,
dapagliflozin 5mg and dapagliflozin 10mg groups was 38.4
(SD 5.7), 37.6 (SD 4.6) and 38.0 (SD 5.0) mL/min/1.73 m2,
respectively. The median UACR was 52.0, 51.0 and 40.0mg/g
in the placebo, dapagliflozin 5mg and dapagliflozin 10mg
groups, respectively. A total of 136 patients (62%) had a
UACR30mg/g.
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Effects of dapagliflozin on glycemic parameters
Dapagliflozin compared with placebo did not change HbA1c.
The least square mean differences between dapagliflozin and pla-
cebo in percent change in HbA1c during the 102-week period
were 0.03% (95% CI 0.3–0.3) for the 5-mg group and 0.03%
(95% CI0.2–0.3) for the 10-mg group. The effect of dapagliflo-
zin compared with placebo on HbA1c was similar when all
patients receiving rescue therapy were excluded.
Effects of dapagliflozin on parameters of kidney function
From baseline to 4weeks, the mean eGFR increased in the
placebo group, whereas in the dapagliflozin 10-mg treatment
group the mean eGFR remained fairly stable (Figure 1A).
Compared with placebo, the mean eGFR change from baseline
after 4weeks of dapagliflozin therapy was 3.6mL/min/
1.73 m2 (95% CI 6.0 to 1.2) for the 5-mg group and
3.8mL/min/1.73 m2 (95% CI 5.9 to 1.7) for the dapagli-
flozin 10-mg group. During the subsequent 72-week follow-up,
eGFR remained lower in both dapagliflozin groups than the
placebo group (Figure 1A). Thereafter, eGFR levels were similar
among the three treatment groups.
In the subgroup of 136 patients with UACR30mg/g, the
difference between dapagliflozin compared with placebo in
UACR was 49.7% (95% CI 66.9 to 23.6) and 30.2%
(95% CI 52.3–2.2) in the 5- and 10-mg groups, respectively,
after 4weeks. This effect was sustained throughout the remain-
ing follow-up period. The least square mean differences between
placebo and dapagliflozin 5 and 10mg during the overall period
were 47.1% (95% CI 64.8 to 20.6) and 38.4% (95% CI
57.6 to 10.3), respectively. The effects of dapagliflozin on
UACR 24weeks post-therapy were consistent in albuminuria
subgroups stratified by baseline median albuminuria level (P of
interaction¼ 0.57) and also in subgroups defined by baseline
micro- and macroalbuminuria (P of interaction¼ 0.26).
Compared with placebo, treatment with dapagliflozin
resulted in an elevation of the least square mean serum
phosphate level by 0.2mg/dL (95% CI 0.1–0.4) for the 5-mg
group and 0.3mg/dL (95% CI 0.1–0.4) for the 10-mg group
(Figure 1C). No clinically relevant change in potassium was ob-
served for either of the dapagliflozin groups (Figure 1D).
Effects of dapagliflozin on other renal and
cardiovascular risk markers
Treatment with both dapagliflozin 5 and 10mg resulted in
an increase in the least square mean hematocrit of 2.5% (95%
CI 1.7–3.3) and 2.5% (95% CI 1.7–3.2), respectively, compared
with placebo, during the overall 102-week period (Figure 2A).
Additionally, dapagliflozin compared with placebo caused a re-
duction in the least square mean systolic BP of 1.4mmHg
(95% CI4.8–2.0) and3.8mmHg (95% CI6.9 to0.7) for
the 5- and 10-mg groups, respectively (Figure 2B). Body weight
decreased progressively in patients receiving dapagliflozin but
increased in the placebo group (Figure 2C). The average reduc-
tion in body weight during the whole period was 1.7 kg (95%
CI 3.0 to 0.4) for the 5-mg dapagliflozin group and 2.2 kg
(95% CI3.4 to1.0) for the 10-mg group compared with pla-
cebo. The reduction in UACR during dapagliflozin therapy was
modestly attenuated after adjustment for HbA1c, systolic BP
and body weight (Table 2). Changes in uric acid were similar
among the three treatment groups (Figure 2D).
Safety
The average time of follow-up varied due to dropout rates
and different studies in the pool including different dose arms.
The average follow-up was 384 days in the placebo arm and 527
and 419 days in the dapagliflozin 5- and 10-mg arms, respec-
tively. The overall rate of adverse events was similar in the three
treatment groups (Table 3). Serious adverse events occurred in
30.4% of patients in the placebo group and 22.4% and 25.8% in
the dapagliflozin 5- and 10-mg groups, respectively. Three
patients receiving placebo (4.3%), one patient receiving dapagli-
flozin 5mg (1.7%) and two patients receiving dapagliflozin
10mg (2.2%) died during follow-up.







Age (years) 66.5 (7.7) 66.0 (9.0) 66.3 (7.4)
Female, n (%) 29 (42.0) 26 (44.8) 44 (47.3)
Race, n (%)
White 60 (87.0) 46 (79.3) 83 (89.2)
Black 1 (1.4) 5 (8.6) 6 (6.5)
Asian 4 (5.8) 2 (3.4) 1 (1.1)
Other 4 (5.8) 5 (8.6) 3 (3.2)
eGFR (mL/min/1.73 m2) 38.4 (5.7) 37.6 (4.6) 38.0 (5.0)
<30 5 (7.1) 4 (6.9) 3 (3.2)
30–<45 64 (91.4) 54 (93.1) 90 (96.8)
Weight (kg) 97.7 (19.6) 97.1 (21.1) 98.2 (20.4)
BMI (kg/m2) 34.6 (5.5) 34.7 (5.9) 34.8 (6.3)
Diabetes duration (years) 13.5 (8.3) 17.2 (9.5) 16.7 (10.3)
HbA1c (%) 8.1 (1.0) 8.4 (1.1) 8.2 (0.9)
Systolic BP (mmHg) 129.7 (15.7) 131.3 (18.5) 134.3 (17.0)
Diastolic BP (mmHg) 73.9 (9.7) 74.0 (9.7) 75.0 (8.5)
Pulse pressure (mmHg) 55.8 (13.9) 57.3 (16.4) 59.3 (16.0)
UACR (mg/g) 52.0 (17.0–180.0) 51.0 (18.0–539.0) 40.0 (9.0–285.0)
Data are mean (SD) unless stated otherwise. UACR values represent median (25th–75th percentile). BMI, body mass index.
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FIGURE 2: Changes in renal or cardiovascular risk markers over time during treatment with placebo or dapagliﬂozin: (A) hematocrit,
(B) systolic blood pressure (SBP), (C) body weight, (D) uric acid.
FIGURE 1: Changes in parameters of kidney function over time during treatment with placebo or dapagliﬂozin: (A) eGFR, (B) UACR,
(C) phosphate, (D) potassium. *UACR analysis (UACR30mg/g): n¼ 42 for placebo, n¼ 37 for dapagliﬂozin 5mg and n¼ 57 for
dapagliﬂozin 10mg. BL, baseline.
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Overall, the proportion of hypoglycemic events was similar
between the three groups. Three patients receiving placebo
(4.3%) experienced a major episode of hypoglycemia, whereas
none of the patients receiving dapagliflozin hadmajor hypoglyce-
mia. Urinary tract infections occurred more frequently in the pla-
cebo group (13%) compared with the dapagliflozin 5- and 10-mg
groups (10.3% and 9.7%, respectively), whereas genital infections
occurred more frequently in the dapagliflozin groups (5.2% and
4.3%, respectively) compared with the placebo group (1.4%). In
the dapagliflozin 10-mg group, more adverse events related to
kidney function occurred (25.8%), versus 13% in the placebo
group and 6.9% in the 5-mg group. Three serious adverse events
of acute renal failure were reported and all three patients received
placebo. There were no differences in adverse events related to
volume depletion (Table 3).
DISCUSSION
The principal finding of this pooled analysis of a large phase 3
program is that in patients with type 2 diabetes and Stages 3b–4
CKD, dapagliflozin decreases albuminuria, BP and body weight.
These beneficial effects were apparent after 4weeks of treatment
with dapagliflozin and generally persisted throughout the 102-
week follow-up period. Dapagliflozin did not decrease HbA1c
compared with placebo treatment, indicating that the observed
effects on albuminuria, BP and body weight are dissociated
from hypoglycemic effects and possibly mediated by natri-
uretic/diuretic mechanisms. eGFR was relatively stable over
time, both with dapagliflozin and placebo treatment.
Dapagliflozin was generally well tolerated in the study popula-
tion. The overall proportion of adverse events was similar
among dapagliflozin- and placebo-treated patients.
Improving glycemic control has been proven to be impor-
tant in reducing the risk of microvascular complications of dia-
betes [19]. In our population of patients with type 2 diabetes
and Stages 3b–4 CKD, dapagliflozin did not improve glycemic
control. Based on this lack of efficacy, SGLT2 inhibitors are cur-
rently not recommended for the treatment of diabetes in
patients with impaired renal function [20–23]. Dapagliflozin,
however, favorably influenced other cardiovascular risk
markers, including BP and albuminuria, in the present study.
Similar findings have been observed with two other SGLT2
inhibitors, empagliflozin and canagliflozin [6, 8]. The magni-
tude of albuminuria reduction was clinically meaningful and,
based on large epidemiological studies, might be expected to
translate into an40% relative risk reduction for end-stage kid-
ney disease [24]. This finding helps to justify a dedicated clinical
outcome trial to investigate the long-term efficacy and safety of
SGLT2 inhibitors in patients with type 2 diabetes and Stages
3b–4 CKD.
Table 2. Mean Percentage change (95% CI) from baseline UACR at Week 24: unadjusted for covariates and adjusted for changes from baseline in HbA1c,







Change from baseline UACR, unadjusted 42.8 (62.2 to 13.5) 71.3 (81.1 to 56.2) 62.6 (75.0 to 44.0)
Change from baseline compared with placebo 49.7 (68.5 to 20.0) 34.6 (57.6–0.9)
Change from baseline UACR, adjusted for HbA1c 33.0 (58.6–8.5) 63.6 (78.2 to 39.4) 51.8 (71.1 to 19.7)
Change from baseline compared with placebo 45.8 (67.3 to 10.1) 28.1 (55.5–16.1)
Change from baseline UACR, adjusted for SBP 33.3 (56.9–3.1) 61.9 (76.0 to 39.4) 49.6 (68.2 to 20.1)
Change from baseline compared with placebo 42.8 (63.9 to 9.5) 24.4 (50.9–16.4)
Change from baseline UACR, adjusted for BW 34.9 (59.3–4.0) 58.8 (75.5 to 30.8) 46.2 (67.6 to 10.6)
Change from baseline compared with placebo 36.7 (62.6–7.0) 17.3 (49.1–34.3)







1 AE 58 (84.1) 53 (91.4) 79 (84.9)
1 SAE 21 (30.4) 13 (22.4) 24 (25.8)
AEs leading to study drug discontinuation 20 (29.0) 13 (22.4) 21 (22.6)
AEs of special interest
Hypoglycemiaa 26 (37.7) 25 (43.1) 29 (31.2)
Urinary tract infection 10 (14.4) 6 (10.3) 9 (9.7)
Genital infection 1 (1.4) 3 (5.2) 4 (4.3)
Renal function 9 (13.0) 4 (6.9) 24 (25.8)
Volume depletion 5 (7.2) 5 (8.6) 7 (7.5)
SAE of special interest
Urinary tract infection 0 1 (1.7) 0
Genital infection 0 0 0
Renal function 4 (5.8) 1 (1.7) 1 (1.1)
Volume depletion 1 (1.4) 0 1 (1.1)
n (%) of adverse events (AEs) and serious adverse events (SAEs).
aTotal subjects with hypoglycemia.
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The mechanisms by which SGLT2 inhibitors reduce body
weight, BP and albuminuria in the absence of glycemic effects
are unknown. It is plausible that the reduction in glucose filtra-
tion resulting from a reduced eGFR decreases the capacity of
SGLT2 inhibitors to inhibit glucose reabsorption. Yet, it
remains unclear why other effects persist in patients with im-
paired kidney function. Such patients may have an increased
sensitivity to the mild natriuretic/osmotic diuresis induced by
dapagliflozin. The DAPASALT trial (NCT03152084), designed
to investigate the mechanism of natriuretic–diuretic effects of
dapagliflozin in patients with preserved and impaired kidney
function, will provide more insight into this issue.
The observed reductions in eGFR, albuminuria and BP
resulting from treatment with SGLT2 inhibitors are thought to
be a clinical manifestation of increased sodium delivery to the
macula densa, which in turn reduces tubuloglomerular feedback
and decreases intraglomerular pressure. In many primary and
secondary kidney diseases, for example, focal segmental glomer-
ulosclerosis, immunoglobulin A (IgA) nephropathy, hyperten-
sive nephrosclerosis and obesity-induced nephropathy,
maladaptive functional renal hemodynamic changes are thought
to occur, including increases in renal blood flow, GFR and filtra-
tion fraction [25]. In these conditions, administration of SGLT2
inhibitors could potentially restore tubuloglomerular feedback,
leading to a reduction in the afferent arterial tone and intraglo-
merular pressure, which can favorably affect long-term renal
prognosis. Hence the increase in the prevalence of non-diabetic
kidney disease in many parts of the world, together with the lack
of glycemic effects of dapagliflozin in patients with CKD Stages
3b–4, makes SGLT2 inhibitors an attractive adjunctive therapy
to angiotensin-converting enzyme inhibitors or angiotensin II
receptor blockers in the broader CKD population.
The overall proportion of adverse events in our study was
similar among patients in the dapagliflozin and placebo groups,
but there were more renal adverse events in patients treated
with dapagliflozin. However, there was no increase in the over-
all serious renal adverse events and no increase in serious acute
renal failure events in the dapagliflozin group compared with
the placebo group. In addition, randomized placebo-controlled
trial data also indicate that the risk of acute kidney injury (AKI)
is not increased during SGLT2 inhibition [5, 26]. Moreover, a
recent registry study reported that SGLT2 use in patients with
type 2 diabetes who were managed in two large health systems
was not associated with an increased risk of AKI [27].
These results are in contrast to the observational reports from
clinical practice that were sent to the US Food and Drug
Administration (FDA) suggesting that SGLT2 inhibitors in-
crease the risk of AKI. In response to these reports, the FDA re-
cently strengthened their AKI warning for SGLT2 inhibitors
[28]. Ongoing large randomized controlled trials in patients
with CKD will provide more definitive evidence as to whether
SGLT2 inhibitors cause AKI.
Our study showed increased phosphate levels with SGLT2
inhibition. The clinical relevance of this effect is unknown. It
has been speculated that this increase in phosphate may precipi-
tate fractures, but recent data with dapagliflozin in patients with
type 2 diabetes indicate no increased fracture risk or increased
rate of bone turnover as assessed by biomarkers [15, 29, 30].
Our results extend prior findings demonstrating that the
effects of SGLT2 inhibitors on HbA1c levels in patients with type
2 diabetes and more severe CKD is attenuated, while effects on
other renal and cardiovascular risk markers persist [6]. We re-
port for the first time the effects of SGLT2 inhibition in a sub-
group of patients with CKD Stages 3b–4 over a 102-week follow-
up. The previous studies including patients with Stage 3 CKD
and a small group of patients with Stage 4 CKD produced similar
reductions in UACR, BP and body weight, but during a shorter
follow-up period [6, 8]. In contrast to the previous studies, which
showed a decline in eGFR during SGLT2 inhibition, we observed
no change in eGFR in the dapagliflozin treatment arms and an
increase in the placebo arm. This is likely to reflect regression to-
wards the mean, because we specifically selected patients with an
eGFR<45mL/min/1.73 m2 at the baseline visit and, as observed
in the placebo arm, the eGFR regressed to the mean at the next
visit. For that reason, we also reported the mean eGFR change
with dapagliflozin relative to placebo. Finally, we observed that a
large proportion of the treatment effect of dapagliflozin on
UACR remained present after adjustment for changes in
HbA1c, systolic BP or body weight. This finding is in line with
previous studies with dapagliflozin and empagliflozin [4, 31].
A limitation of this study was the relatively small study pop-
ulation. Second, the majority of the population was at relatively
low risk of renal endpoints, as reflected by the large number of
patients with normoalbuminuria. This likely explains the slow
rate of eGFR decline both in the placebo and dapagliflozin treat-
ment groups. Not all of the studies in this pooled analysis exam-
ined the effects of both dapagliflozin 5 and 10mg. The data on
dapagliflozin 10mg came primarily from two studies in patients
at high cardiovascular risk, while the data on dapagliflozin 5mg
came from a clinical trial in patients with predominantly Stages
3a–b CKD. This difference in background characteristics in the
populations may have influenced the safety comparison be-
tween dapagliflozin 5 and 10mg.
In conclusion, dapagliflozin did not decrease HbA1c in
patients with type 2 diabetes and Stages 3b–4 CKD in this
post hoc analysis. However, it decreased UACR, BP and body
weight without major side effects. These actions of dapagliflozin
support the need for a large outcome trial in this population to
confirm long-term safety and efficacy in reducing adverse clini-
cal endpoints.
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